NeoImmuneTech, Inc.
4:45 PM - 5:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
NeoImmuneTech (NIT) is a T-cell Centric IO Company and the Global Leader in Interleukin (IL-7). At NIT, we strive to expand the therapeutic horizon in Immuno-Oncology and Infectious Diseases by greatly reducing the fatality and morbidity of life-threatening and debilitating diseases.
Led by our scientific founder, who invented our lead asset NT-I7 (efineptakin alfa), we are science driven and patient focused.
We believe that with NT-I7, the only clinical-stage long-acting human IL-7, we can enhance the body’s immune function
to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.
Led by our scientific founder, who invented our lead asset NT-I7 (efineptakin alfa), we are science driven and patient focused.
We believe that with NT-I7, the only clinical-stage long-acting human IL-7, we can enhance the body’s immune function
to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.
Ticker:
XKRX: 950220
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Oncology
Lead Product in Development:
NT-I7
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
